Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein

Area of Science:

• Immunology
• Molecular Biology
• Virology

Background:

• Cytotoxic T Lymphocytes (CTLs) recognize viral epitopes presented on MHC class I molecules.
• Epitope generation typically involves proteasomal degradation of polypeptides.
• The Defective Ribosomal Product (DRiP) hypothesis proposes epitopes arise from newly synthesized, rapidly degraded proteins.

Purpose of the Study:

• To investigate if new synthesis (neosynthesis) is essential for presenting the immunodominant epitope NP118 from the lymphocytic choriomeningitis virus (LCMV) nucleoprotein.
• To test a key prediction of the DRiP hypothesis regarding epitope generation.

Main Methods:

• Utilized a tetracycline-regulated transfectant system to control LCMV nucleoprotein biosynthesis.
• Terminated nucleoprotein synthesis and monitored the presentation of the NP118 epitope.
• Assessed epitope presentation after a significant period following the cessation of protein synthesis.

Main Results:

• Presentation of the NP118 epitope ceased two days after terminating nucleoprotein biosynthesis.
• The long half-life (>3 days) of the LCMV nucleoprotein did not lead to sustained epitope presentation.
• Epitopes were derived from newly synthesized nucleoproteins, not the existing long-lived protein pool.

Conclusions:

• The findings demonstrate that neosynthesis is required for the presentation of the LCMV NP118 epitope.
• This study provides the first experimental evidence supporting the DRiP hypothesis's requirement for neosynthesis using a specific viral substrate.
• The LCMV nucleoprotein serves as a model to validate the DRiP hypothesis in epitope generation.